

Contents

Preface	iii
Author Acknowledgments	v
 Chapter 1: Introduction	 1
<i>Koen Cobbaert, MSc, and Gert Bos, PhD, MSc, FRAPS</i>	
 Chapter 2: Software as a Medical Device	 5
<i>Pat Baird, MSc, MBA; Koen Cobbaert, MSc; Zhuo Li, MSc</i>	
Introduction	5
SaMD Versus SiMD	5
SaMD for Population Health	6
SaMD in the US	6
SaMD in Canada	7
MDSW in the EU	7
SaMD in China	8
Modules	9
Wearables	10
Scenario 1: Wearable and Software Are an Integral Part of a Medical Device	11
Scenario 2: Wearable Is an Accessory for SaMD/MDSW	11
Scenario 3: Software Is an Accessory for a Medical Device Wearable	12
Scenario 4: Only Software Is a Medical Device, Wearable Not Subject to Regulation	12
Scenario 5: Wearable and Software Are Placed on the Market as a System	13
Conclusion	13
 Chapter 3: Software as an IVD Medical Device	 15
<i>Christie Hughes, MPH, MLS(ASCP), RCC-IVDR, and Henk-Willem A. Mutsaers</i>	
Introduction	15
Qualification of IVD Software as an IVD SaMD	15
Qualification of IVD Software in the EU	15
Qualification of IVD Software in the US	17
Qualification of IVD Software in Canada	18
Defining the Intended Purpose for an IVD SaMD	19
Constructing the Intended Use Statement	19
Identifying Claims and Benefits for the IVD SaMD	21
IVD SaMD Classification	21
Classification of IVD SaMD in the US	21
Classification of IVD SaMD in Canada	24
Classification of IVD MDSW in the EU	24
Artificial Intelligence and Machine Learning for IVDs	25
Performance Evaluation and Clinical Evidence for IVD SaMD	25
Clinical Association of IVD SaMD	26

Analytical Performance of IVD SaMD.....	27
Clinical Performance of IVD SaMD	27
Conclusion	28

Chapter 4: Classification of Medical Device Software 31

Koen Cobbaert, MSc

Introduction	31
Code-Based Classification.....	31
Rule-Based Classification.....	31
Classification Following EU MDR and EU IVDR	31
Medical Device Software	32
Implementing Rules in EU MDR	33
Administration Medical Device Classification Catalog	33
Definition of Drive or Influence the Use.....	34
Types of Drive or Influence the Use.....	35
Dependent MDSW	35
Independent MDSW	36
Classification Rule 11.....	37
Scope of Rule 11a.....	37
Interpretation of Rule 11a	38
Interpretation of IMDRF SaMD Risk Framework	38
Interpretation Issues of IMDRF SaMD Risk Framework	39
Rule 11b	40
Rule 11c.....	40
Impact of Rule 11.....	40
Classification Rule 12.....	40
Classification Rule 15.....	41
Classification Rule 22.....	41
Helsinki Procedure	43
Class Implications	44
Conclusion	45

Chapter 5: Clinical Evaluation of Software..... 49

Zuzanna Kwade, PhD, MSc

Introduction	49
General Principles of Clinical Evaluation	49
Specific Guidelines for SaMD Clinical Evaluation.....	50
Considerations for Artificial Intelligence	52
Regulations.....	53
Conclusion	56

Chapter 6: Safety Risk Management of Software 59

Mikael Dahlke, MSc, and Robert Ginsberg, MSc

Introduction	59
The History of Software Safety Risk Management	60
1985-1987: Therac-25: Software Controlling a Therapy Device.....	60
2001: Multidata, National Cancer Institute, Panama City: Radiation Planning Software	60
2020: COVID-19 Tests.....	61
Summary	61
Aspects of Software in Risk Management According to ISO 14971	61
Hazardous Situation Example.....	61
Examples	62
Challenges With Software Risk Assessment.....	62
Challenges With Analyzing Hazards Causing Indirect Harm.....	62
Challenges Related to ML Medical Devices.....	63
Challenges With Probability Estimates for Software.....	63

Challenges With Single-fault Safety of SaMD.....	64
Challenges With Finding Appropriate Risk Control Measures for Software	65
Strategies for Successful Software Risk Assessment.....	66
Strategies for Handling Hazards Causing Indirect Harm.....	66
Strategies for Managing Estimation of Probability of Software Errors.....	66
Strategies for Managing Single-Fault Conditions.....	67
Strategies for Risk Control Measures in SaMD.....	67
Improving Software Quality.....	68
IEC 62304.....	68
FDA	68
Other Industries	68
Front-loading	68
Semiformal Methods.....	68
Failure Assertion Programming.....	68
Selection of Programming Language	68
Coding Guidelines	68
Test-Driven Development.....	69
Continuous Integration.....	69
Conclusion	70
Chapter 7: Security Risk Management	73
<i>Ben Kokx</i>	
Introduction	73
SaMD Security.....	73
Security Risk Management	75
Security by Design	75
Threat Modeling.....	76
Vulnerability Handling and Security Monitoring	76
Total Product Lifecycle	79
Shared Responsibility.....	79
Standards.....	79
Overlapping Legislative Security Requirements	80
Conclusion	80
Chapter 8: Software Development	83
<i>Coenraad Davidsdochter, MSc</i>	
Introduction	83
Standards and Guidance.....	83
Definitions.....	84
Software Development Process	85
User Needs	86
Software Development Planning.....	86
Requirements Management	87
Architectural Design	88
Configuration Management.....	88
Design Reviews	88
Safety and Agile	88
Risk Management	88
Gated Development and Agile.....	90
Usability Engineering.....	91
Software Validation	93
Postmarket Activities.....	94
Medical and Nonmedical Software Functions.....	95
Software Incorporating AI and/or Machine Learning.....	95
Requirements for AI-Enabled Medical Devices	95
Conclusion	96
Author Acknowledgment.....	96

Chapter 9: Open Source and Third-Party Software	99
<i>Siegfried Schmitt, PhD</i>	
Introduction	99
Terminology	99
Discussion	99
What Are the Concerns About Open-Source Software Components?.....	100
What Are the Concerns About Third-Party (Commercial) Software Components?	100
AI components	101
Case Studies	102
Conclusion	104
 Chapter 10: User Experience Design	 107
<i>Koen Cobbaert, MSc</i>	
Introduction	107
Why User Experience Design?.....	107
Simpler and Smarter	107
Human Oversight	108
Automation Bias.....	109
Transparency and Interpretability of Output.....	109
Design for Happiness	111
Usability and User Interfaces	112
Intended User.....	112
Personas	112
User Needs, Requirements, and Specifications	112
Roles and Responsibilities	113
User Experience Design Specialist	114
Identifying Usability-Sensitive User Needs	115
Use Scenarios	115
Usability Goals	116
Documenting Usability Goals	116
Usability Evaluation	117
User Interface Requirements and Design Specifications	117
Formative Evaluation	118
User Observation.....	118
Walkthrough Evaluation	119
Heuristics Analysis	119
Severity Scale.....	120
Design Principle #1: Focus on Core Functionality	121
Design Principle #2: Understandability Before Simplicity	121
Design Principle #3: Self-Evident and Self-Learnable	122
Design Principle #4: Mobile First	122
Information Architecture Principles.....	123
Verification and Validation	123
Number of Testers	123
Tester Training	123
Single Ease Question	123
Product Reaction and Word Association Cards	123
System Usability Score	124
Acceptance Criteria	125
Product Safety Risk Management.....	127
Regulatory Standards and Requirements.....	127
Conclusion	128
Acknowledgement.....	128
 Chapter 11: Artificial Intelligence	 131
<i>Koen Cobbaert, MSc</i>	
Introduction	131

Role of AI in Healthcare	131
AI Techniques	132
Natural Language Processing	132
Generative AI	133
AI System	133
AI Model	134
General Purpose AI Models	134
Foundation Model	136
Global Versus Local Change	136
Federated Learning	136
Change Dynamics	137
Adaptive Medical Devices	138
Predetermined Change Control Plan	139
AI-Enabled Commoditization of Medical Device Manufacturing	139
Medical Device Production System	140
A Future for Generalist Medical AI Systems	140
Challenges to the Adoption of GMAI Systems	140
International Medical Device Regulators Forum's AI/ML Working Group	141
AI-based Medical Devices in China	141
Risk-Based Approach of AIA	142
AIA's Stakeholders	143
AIA Joint Conformity Assessment of High-Risk AI Systems	143
Requirements for Providers of High-Risk AI Systems	146
The Role of AI Standards	147
AIA Obligations for Deployers of High-Risk AI Systems	147
Conclusion	147
Chapter 12: Quality and Reliability of Health Apps	151
<i>Petra Hoogendoorn, MSc, and Charles McCay</i>	
Introduction	151
CEN ISO/TS 82304-2:2021	151
Label2Enable	152
Conclusion	152
Chapter 13: Data Governance and Management	155
<i>Leon Doorn, MSc, and Jouke Waleson</i>	
Introduction	155
Defining Data	155
Definitions	155
Data Management Use Cases	157
Roles and Responsibilities	160
Legal Representative	160
Data Protection Officer	160
Quality Affairs/Regulatory Affairs	160
Security Officer	161
Data Scientists	162
Other AI-Specific Data Roles	162
Software Engineers	162
Clinical Specialist	162
Management Representative	163
Data Requirements Framework	163
Current Data Legislation	163
Specific Data Legislation	164
Other Data Protection Legislation	167
Non-Data-Specific Legislation	168
Legislation Under Development	171
AI Data Management Standards	171

ISO/IEC	171
IEEE	172
CTA	172
Data Management in Practice	173
Cloud, Self-Hosting, or Managed Hosting	173
Data Register.....	173
Data Expiration Policies.....	173
Traceability and Identification	174
PII, PHI, Pseudonymization, Anonymization.....	175
Data Breaches.....	175
Conclusion	175

Chapter 14: Digital Supply Chains and Their Regulatory Implications179

Koen Cobbaert, MSc

Introduction	179
Digital Distribution and Supply-Chain Accountability	179
Horizontal Digital Rules in the Medical Device Supply Chain	179
Regulatory Trigger Points: Placing on the Market Versus Putting Into Service.....	180
Why Definitions Matter: Legislative Scope and Operator Responsibilities.....	181
Physical Supply Chains and Regulatory Trigger Points	182
Labeling and Traceability Obligations for Software on Physical Media	182
Digital Supply Chains and Governance	182
Digital Supply Chains and Regulatory Trigger Points	182
Distance Sales.....	183
Information Society Services.....	183
When Software Breaks the Sequence: Updates and Modules.....	183
Use Case 1 – Hardware With Embedded Software (Integrated Product).....	184
Use Case 2 – Separate Hardware and Software Integrated at Installation	185
Use Case 3 – Independent Software (Software-Only Offering).....	186
Economic Operators in Traditional Supply Chains.....	187
Economic Operators in Digital Supply Chains.....	191
Importer and Distributor Obligations.....	192
Online Platform Provider Obligations	194
Gatekeeper Obligations.....	197
Deployer Obligations	198
Conclusion	198
Author Acknowledgment.....	198

Chapter 15: Market Access and Reimbursement Pathways for Digital Health Technologies.....201

Catarina Carrão, FAHA

Introduction	201
Market Authorization Versus Market Access.....	201
Coverage and Health Technology Assessment (HTA).....	202
Specifics of Reimbursement Pathways for DHTs Across EU Member States	203
Health Technology Assessment (HTA) Regulation, EDiHTA, and ASSESS-DHT	206
Outside of the EU Member States: Global Reimbursement Landscape.....	207
UK	207
South Korea	207
Japan	207
US	207
Conclusion	208

Chapter 16: Software Liability211

Agnes Szoboszlai, LLM, and Uta Rawson, JD

Introduction	211
Product Liability.....	211
Software as a Product	212

Defectiveness of Software as a Product	212
Manufacturer of a Defective Product and Other Potential Defendants	214
Fault-Based Liability	215
Not Complying with Legal Requirements, Acting Unreasonably	215
Links Between the PLD and MDR/IVDR	217
Medical Accidents, Liability of Medical Professionals	217
Liability in Contract	217
Product Liability in the US	218
Conclusion	218
Acknowledgment	219
Index	221

Figures

Figure 2-1. Regulatory Fragmentation of Software as a Medical Device	5
Figure 2-2. App to Detect Fever	6
Figure 2-3. Categories of SaMD and SiMD	9
Figure 2-4. A PACS System With Two Plugins	10
Figure 2-5. Scenario 1: Wearable and Software Are an Integral Part of a Medical Device	11
Figure 2-6. Scenario 2: Wearable Is an Accessory for SaMD/MDSW	11
Figure 2-7. Scenario 3: Software as an Accessory for Medical Device Wearable	12
Figure 2-8. Scenario 4: Only Software Is a Medical Device, Wearable Not Subject to Regulation	13
Figure 2-9. Scenario 5: Wearable and Software Are Placed on the Market as a System	13
Figure 3-1. Decision Steps to Assist Qualification as an IVD or MD MDSW for the EU	16
Figure 3-2. Example of FDA IVD Generic Device Type Regulation	22
Figure 3-3. Example of FDA Product Classification Database Search and Results	23
Figure 4-1. Illustration of a Selection of FDA Product Codes That Comprise Software Applications	32
Figure 4-2. Overview of EU IVDR Classification Rules	34
Figure 4-3. Overview of EU MDR Classification Rules	35
Figure 4-4. Digital Thermometer With a Fever Alert Function	36
Figure 4-5. Insulin Dose Calculator App That Drives an Insulin Pump	36
Figure 4-6. An X-Ray System Comprised of Dependent and Independent Software	37
Figure 4-7. An Accessibility App for Patients With Locked-In Syndrome	38
Figure 4-8. Illustration of How EU MDR Rule 11a Maps on the IMDRF SaMD Risk Framework	39
Figure 4-9. Examples of SaMD Mapped Against IMDRF Risk Framework	40
Figure 4-10. Industry Interpretation of SaMD Risk Framework	41
Figure 4-11. Conformity Assessment Procedures Under EU MDR Article 52	42
Figure 4-12. Illustration of the Extent of Notified Body Review for Increasing Device Classification	43
Figure 4-13. Path to Market in the US According to Device Class	44
Figure 5-1. Clinical Evaluation Process	50
Figure 5-2. Clinical Evidence Components for SaMD	51
Figure 6-1. Sequence of Events for an IVD Device	65
Figure 6-2. Figure Assertion Programming	69
Figure 7-1. SaMD Security	74
Figure 7-2. Security Monitoring Flowchart	78
Figure 8-1. Software Development According to the Waterfall Approach	86
Figure 8-2. Software System Decomposition Into Software Items	89
Figure 8-3. IEC 62304 Development Processes for Incremental Execution	90
Figure 8-4. Mapping IEC 62304 Software Development Process Steps to Agile Increments	91
Figure 8-5. IEC 62304 and IEC 62366-1 Development Processes for Incremental Execution	92
Figure 8-6. Figure 2 of the FDA's Proposed Regulatory Framework for Modifications to Artificial Intelligence/ Machine Learning	96
Figure 9-1. Device Use Concept	103
Figure 10-1. Types of Controllability	108
Figure 10-2. Transparency and Interpretability of an AI system's output	110
Figure 10-3. Design for Happiness	111
Figure 10-4. Relationship Between User Needs, Requirements, and Design Specifications	113

Figure 10-5. Examples of Usability Roles and Responsibilities	113
Figure 10-6. Example of a Process Representing Activities Related to User Experience Design	114
Figure 10-7. Relationship Between User Needs, Usability-Sensitive User Needs, Use Scenarios, and Usability Goals	115
Figure 10-8. Examples of User Interface Requirements	117
Figure 10-9. Example Table of Contents for a Template to Document User Observations	118
Figure 10-10. Example of a Walkthrough Evaluation	119
Figure 10-11. Walkthrough Example Involving a Scenario With Different Tasks	120
Figure 10-12. Example of Usability Severity Scale.....	122
Figure 10-13. Single Ease Question (SEQ)	124
Figure 10-14. Intuitive SUS Score Graph	125
Figure 10-15. SUS Scale Interpretation	125
Figure 11-1. A Simplified Diagram of Different AI Techniques.....	132
Figure 11-2. Countries Adhering to AI Principles.....	134
Figure 11-3. Scheme with Criteria and Examples to Qualify Software as an AI System.....	135
Figure 11-4. Global and Local Model Change	136
Figure 11-5. Visualization of Federated Learning.....	137
Figure 11-6. AI-based Medical Devices.....	138
Figure 11-7. Overview of NMPA Guidelines and Standardization Applicable to AI-based Medical Devices For Use in China.....	142
Figure 11-8. Visualization AI System Qualification and Classification	143
Figure 11-9. Boolean representation of AIA Article 6.3 exemption criteria.	144
Figure 11-10. Decision Tree for Biometric Categorization System Qualification.....	145
Figure 11-11. Visualization of AIA Stakeholders	146
Figure 12-1. CEN ISO/TS 82304-2:2021 Health App Quality Label.....	152
Figure 13-1. The Relationship Between Different Types of Data.....	156
Figure 13-2. The Primary Data Lifecycle	157
Figure 13-3. A Schematic Classification of Legislation Affecting Data.....	163
Figure 13-4. A Schematic Representation of the Relationship Between the Data Act, the Data Governance Act, and the EHDS	164
Figure 13-5. Schematic Representation of Data Processing Agreements.....	165
Figure 13-6. Schematic Representation of an EU Controller Contracting a Non-EU-Based Processor, *in a Country Where No Adequacy Decision Is in Place (DPA + SCC).....	165
Figure 13-7. Example Relationship Between Covered Entities and Business Associate Agreements (Where SAAS Refers to Software as a Service).....	167
Figure 13-8. (A) Simplified Overview of the Plan-Do-Check-Act Cycle and How Data Are Used to Support a Quality Management System; (B) Specific Example Using Customer Feedback (Complaint) Data	170
Figure 14-1. Hardware With Embedded Software	184
Figure 14-2. Separate Hardware and Software Integrated at Installation	185
Figure 14-3. Independent Software (Software-Only Offering).....	186
Figure 14-4. Visualization of Economic Operators and Their Interactions Under the Union Harmonized Legislation.....	187
Figure 14-5. Clinical Investigation Governance for a Third-Country Manufacturer's Investigational Device Not Yet Placed on the Union Market.....	190
Figure 14-6. Measures for Consideration Under MDCG 2025-4	197

Tables

Table 3-1. Relevant Definitions in Canada	19
Table 3-2. Example of Intended Use Element Breakdown	20
Table 3-3. Example of Claims and Benefits List.....	21
Table 3-4. FDA Device Risk Classifications	22
Table 3-5. AI Act Classification Rules for High-Risk IVD AI Systems (MDAI).....	25
Table 4-1. Translation of the Software Categories in the Software Chapter 21 of China's NMPA's National Medical Products.....	33
Table 4-2. The Type and Frequency of Reporting to Competent Authorities Based on Risk Class in the EU	45
Table 5-1. Guidelines and Standards Relevant for the Generation of Clinical Evidence and Clinical Evaluation of SaMD	55
Table 6-1. Probability	62
Table 6-2. Qualitative and Semiquantitative Probability	62
Table 6-3. Example Severity Scale.....	62

Table 6-4. Example Risk Matrix	63
Table 6-5. Typical Hazards of In Vitro Diagnostic Software	63
Table 6-6. Example Software Risk Assessment.....	64
Table 6-7. Examples of Diagnosis and Factors to Consider in the Severity Assessment.....	66
Table 10-1. Examples of Usability Goals.....	116
Table 10-2. Heuristics Report Example	121
Table 10-3. System Usability Score (SUS)	124
Table 10-4. Acceptance Criteria Examples	126
Table 11-1. Comparative Overview of Current AI Regulatory Policy. Simplified and based on the Centre d'Expertise International de Montréal en Intelligence Artificielle (CEIMIA) Assessment.....	131
Table 11-2. Various Definitions for AI Systems.....	135
Table 11-3. FDA's Components of a Predetermined Change Control Plan.....	139
Table 13-1. Overview of Regulatory Requirements for DPO Appointment.....	161
Table 13-2. Overview of Data Retention Periods.....	162
Table 13-3. Overview of Sections Addressing Data Regulations	163
Table 13-4. Overview of Data Legislation	164
Table 13-5. Overview of data breach notification requirements	174
Table 14-1. Definition of <i>Placement on the Market</i> According to Various EU Legislations	180
Table 14-2. Definition of <i>Making Available</i> According to Various EU Legislations	181
Table 14-3. Definition of <i>Putting Into Service</i> According to Various EU Legislations	181
Table 14-4. Definition of <i>Manufacturer</i> According to Various EU Legislations.....	188
Table 14-5. Definition of <i>Importer</i> According to Various EU legislations	188
Table 14-6. Definition of <i>Distributor</i> According to Various EU Legislations	189
Table 14-7. Definition of <i>Fulfillment Service Provider</i> According to Various EU Legislations.....	189
Table 14-8. Deployer Definition According to Various EU Legislations	191
Table 14-9. Provider Definition According to Various EU Legislations	191
Table 14-10. Definition of <i>Intermediary Services</i> According to Various EU Legislations	192
Table 14-11. Definition of Online Platform According to Various EU Legislations	193
Table 14-12. Comparison of Importer Obligations Under the EU AIA and the EU MDR	194
Table 14-13. Comparison of Distributor Obligations Under the EU AIA and the EU MDR.....	195
Table 15-1. Digital Health Technologies Categorization and Impact.....	202
Table 15-2. Health Technology Assessment Core Model Framework (EUnetHTA)	203
Table 15-3. EDiHTA Principles	206

1

Introduction

Koen Cobbaert, MSc, and Gert Bos, PhD, MSc, FRAPS

The current world, where almost all medical devices and in vitro diagnostic (IVD) devices are connected, is changing more rapidly than ever before, with the rapid onset of artificial intelligence (AI) in virtually all aspects of our modern-day society. The new horizon features AI-enhanced products, AI-supported assessment and decision tools, and various AI products that, in one way or another, support the healthcare system and providers, allowing, for example, longer periods of independent and assisted living. Soon after its global public launch, the fast-developing technology cannot be disconnected from our healthcare world as we enter the second quarter of the 21st century.

Today's connectivity of medical devices enables manufacturers to migrate essential and supporting functionality from the device's computing resources to personal computers, handheld devices, cloud servers, wearables, and other products in the Internet of Things. Those external computing platforms often offer more powerful capabilities and are easier to use, maintain, scale, and upgrade. Such medical device software enhances the original medical device's capabilities and performance. The onset of AI in computing and data analysis brings opportunities but also initially poses significant regulatory challenges, which the regulatory world is working hard to overcome.

As manufacturers have centralized almost everything that can be centralized, we are starting to see the opposite trend. As software gets more powerful and data-hungry, it clogs the data pipelines. At the same time, its connectivity may pose privacy, general, and cybersecurity challenges. Software manufacturers are now increasingly offloading functionality, computation, and data storage onto the spare computing resources of medical devices and wearables, close to where the raw data is generated. Such distributed computing is known as edge computing. Decentralized machine learning will further amplify this trend. The wider use of AI, beyond its subset of machine learning, is further accelerating the speed of change and innovation.

Manufacturers' flexibility in choosing where computing occurs and in how they bundle and sell software functionality

or assign medical claims creates a certain degree of device fluidity. This trend will further intensify as continuous machine learning and broader AI support enhance the capabilities of medical devices. Alignment and further interpretative guidance are needed to help us all continue on our way to ensure such devices are safe and perform as intended. As data is getting central in the regulatory debate, AI-enabled devices ride on the crest of the wave of finding real world evidence, typically more pronounced after market launch. Postmarket is the new truth serum – where lifecycle management turns real-world data into a continuous evidence engine.

Postmarket is the new truth serum – where lifecycle management turns real-world data into a continuous evidence engine.

The International Medical Device Regulators Forum¹ created the term Software as a Medical Device (SaMD) for regulatory purposes. The IMDRF work intended to enable a uniform language, common definitions, and regulatory concepts. It has partially achieved those goals, prompting jurisdictions to adjust general concepts to SaMD's specific needs. Nevertheless, definitions vary somewhat, and some jurisdictions have added specific terminology. Also, of course, nowadays wearables take flight. In **Chapter 2**, Pat Baird, Koen Cobbaert, and Zhuo Li explain the foundations of SaMD, share their views on the modularization of medical device functionality, and discuss the regulatory status of wearables.

As software and, in particular, AI is eating the medical device world, the in-vitro diagnostics (IVD) arena follows